celyad 2020

3.397 Posts, Pagina: « 1 2 3 4 5 6 ... 65 66 67 68 69 70 71 72 73 74 75 ... 166 167 168 169 170 » | Laatste
Speedbul
1
@Twin. For the DEPLETHINK trial, 2 new centres in Belgium have been added (Antwerp and Brugge) and 1 US center has changed status from "not yet recruiting" to "recruiting".
So in total we have 8 centres out of which 4 are "recruiting" in the US and 4 sites in Belgium (2 are "recruiting" and the 2 new ones are "not yet recruiting").
The total anticipated number of patients is 52 out of which 9 patients (6 with dose 1 and 3 with dose 2) USING THE mAb MANUFACTURING PROCESS were enrolled at the time of the meeting "meet the management" from 8/1/2020. The comments from Frédéric Lehmann during the presentation = "the results are not very encouraging" with the mAb manufacturing process..
Since then (July 2019), Celyad received the green light to use the OPTIMAB MANUFACTURING PROCESS which will be used for all new patients: 3 other patients at dose 2 and all patients at dose 3.
Now that Celyad is extending the number of trial centers to 8 may suggest that the OptimAb process is boosting the performance.
One billion cells per infusion cohort to begin in Q1 2020 - autologous + preconditionning + OptimAb process with CYAD-01
Twin
0
Speedbul
0
Hi Twin, I believe so.... and we should know more on Tuesday evening through the following webcast

9th Annual SVB Leerink Global Healthcare Conference
Date: Tuesday, February 25, 2020
Presentation time: 3:30 p.m. ET
Location: New York
Twin
0
Burr
0
uw4ever
0
The comments from Frédéric Lehmann during the presentation = "the results are not very encouraging
Lijkt me toch niet positief?
Wittman
0
quote:

uw4ever schreef op 24 februari 2020 09:50:


The comments from Frédéric Lehmann during the presentation = "the results are not very encouraging
Lijkt me toch niet positief?

Graag de daaropvolgende zin ook meenemen in de context: "Since then (July 2019), Celyad received the green light to use the OPTIMAB MANUFACTURING PROCESS which will be used for all new patients: 3 other patients at dose 2 and all patients at dose 3. Now that Celyad is extending the number of trial centers to 8 may suggest that the OptimAb process is boosting the performance."
Speedbul
0
The results of Deplethink with the mAb manufacturing Process were not very encouraging COMPARING to the THINK STUDY(without preconditionning); meaning that it seem's that the preconditionning was not adding much value.
Now with the use of the OptimAb Manufacturing process, it may be another story...
Speedbul
0
Remember that ARMISTICE has still 300.000 shares as shortsell.
By looking at this morning's volume, Armistice may be active today
Wittman
0
quote:

Speedbul schreef op 24 februari 2020 10:37:


Remember that ARMISTICE has still 300.000 shares as shortsell.
By looking at this morning's volume, Armistice may be active today

Agreed – although I don't see one reason why they (Armistice) should have any more insights or knowledge than all other investors combined.
Twin
0
Twin
0
Twin
0
twopence
0
Zit pas in phase 1 Twin heeft toch nog wat tijd nodig. Ik zit zelf ook al op heel veel hopen en begin nu toch wel naar positief resultaat te verlangen. :-))
Twin
0
@2pence misschien morgen nieuws van de conferentie? Eens goed nieuws, de echte doorbraken en geen verwachtingen , dat zou ons deugd doen
3.397 Posts, Pagina: « 1 2 3 4 5 6 ... 65 66 67 68 69 70 71 72 73 74 75 ... 166 167 168 169 170 » | Laatste
Aantal posts per pagina:  20 50 100 | Omhoog ↑

Plaats een reactie

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Detail

Vertraagd 15 jan 2021 17:35
Koers 7,050
Verschil +0,100 (+1,44%)
Hoog 7,050
Laag 6,910
Volume 20.158
Volume gemiddeld 42.775
Volume gisteren 36.937

Brussel real time stocks quotedata by Euronext. Other real time EU stocks, by Cboe Europe Ltd.; US stocks by NYSE & Cboe BZX Exchange, 15 min. delayed
#/^ Index indications calculated real time, zie disclaimer, streaming powered by: Infront